Enhanced chemokine-receptor expression, function, and signaling in healthy African American and scleroderma-patient monocytes are regulated by caveolin-1

Fibrogenesis and Tissue Repair

Volumn 8, Issue 1, 2015, Pages

  Lee, Rebecca ^a   Reese, Charles ^a   Perry, Beth ^a   Heywood, Jonathan ^a   Bonner, Michael ^a   Zemskova, Marina ^a   Silver, Richard M ^a   Hoffman, Stanley ^a   Tourkina, Elena ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CAVEOLIN 1; CD68 ANTIGEN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR3; HEAT SHOCK PROTEIN 47; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; PROTEIN KINASE LYN; PROTEIN TYROSINE KINASE;

AFRICAN AMERICAN; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CELL MIGRATION; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG FIBROSIS; MONOCYTE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCLERODERMA; SIGNAL TRANSDUCTION; SKIN FIBROSIS; UPREGULATION;

EID: 84936858751     PISSN: None     EISSN: 17551536     Source Type: Journal    
DOI: 10.1186/s13069-015-0028-7     Document Type: Article

References (42)

1. Silver RM. Interstitial lung disease of systemic sclerosis. Int Rev Immunol. 1995;12(2-4):281-91.
2. Beall AD, Nietert PJ, Taylor MH, Mitchell HC, Shaftman SR, Silver RM, et al. Ethnic disparities among patients with pulmonary hypertension associated with systemic sclerosis. J Rheumatol. 2007;34(6):1277-82.
3. Nietert PJ, Mitchell HC, Bolster MB, Shaftman SR, Tilley BC, Silver RM. Racial variation in clinical and immunological manifestations of systemic sclerosis. J Rheumatol. 2006;33(2):263-8.
4. Krishnan E, Furst DE. Systemic sclerosis mortality in the United States: 1979-1998. Eur J Epidemiol. 2005;20(10):855-61. doi:10.1007/s10654-005-2210-5.
5. Laing TJ, Gillespie BW, Toth MB, Mayes MD, Gallavan Jr RH, Burns CJ, et al. Racial differences in scleroderma among women in Michigan. Arthritis Rheum. 1997;40(4):734-42. doi:10.1002/1529-0131(199704)40:4<734::AIDART20> 3.0.CO;2[-]3.
6. Mayes MD, Lacey Jr JV, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003;48(8):2246-55. doi:10.1002/art.11073.
7. Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am. 2003;29(2):239-54.
8. Steen V, Domsic RT, Lucas M, Fertig N, Medsger TA, Jr. A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis. Arthritis Rheum.64(9):2986-94. doi:10.1002/art.34482
9. August P, Suthanthiran M. Transforming growth factor beta and progression of renal disease. Kidney Int Suppl. 2003;87:S99-104.
10. Reese C, Perry B, Heywood J, Bonner M, Visconti RP, Lee R, et al. Caveolin-1 deficiency may predispose African Americans to systemic sclerosis-related interstitial lung disease. Arthritis Rheumatol. 2014;66(7):1909-19. doi:10.1002/art.38572.
11. Tourkina E, Bonner M, Oates J, Hofbauer A, Richard M, Znoyko S, et al. Altered monocyte and fibrocyte phenotype and function in scleroderma interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide. Fibrogenesis & Tissue Repair. 2011;4(1):15. doi:10.1186/1755-1536-4-15.
12. Tourkina E, Richard M, Oates J, Hofbauer A, Bonner M, Gooz P, et al. Caveolin-1 regulates leucocyte behaviour in fibrotic lung disease. Ann Rheum Dis. 2010;69(6):1220-6. doi:10.1136/ard.2009.117580.
13. Tourkina E, Richard M, Gooz P, Bonner M, Pannu J, Harley R, et al. Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol. 2008;294(5):L843-61. doi:10.1152/ ajplung.00295.2007.
14. Wang XM, Zhang Y, Kim HP, Zhou Z, Feghali-Bostwick CA, Liu F, et al. Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J Exp Med. 2006;203(13):2895-906. doi:10.1084/jem.20061536.
15. Lee R, Perry B, Heywood J, Reese C, Bonner M, Hatfield CM, et al. Caveolin-1 regulates chemokine receptor 5-mediated contribution of bone marrowderived cells to dermal fibrosis. Frontiers in Pharmacol. 2014;5:140. doi:10.3389/fphar.2014.00140.
16. Olson TS, Ley K. Chemokines and chemokine receptors in leukocyte trafficking. Am J Physiol Regul Integr Comp Physiol. 2002;283(1):R7-28. doi:10.1152/ajpregu.00738.2001.
17. Kumar P, Hosaka S, Koch AE. Soluble E-selectin induces monocyte chemotaxis through Src family tyrosine kinases. J Biol Chem. 2001;276(24):21039-45. doi:10.1074/jbc.M009099200.
18. Distler JH, Akhmetshina A, Schett G, Distler O. Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis. Rheumatology. 2009;48(2):98-103. doi:10.1093/rheumatology/ken401.
19. Lee R, Reese C, Bonner M, Tourkina E, Hajdu Z, Riemer EC, et al. Bleomycin delivery by osmotic mini-pump: similarity to human scleroderma interstitial lung disease. Am J Physiol Lung Cell Mol Physiol. 2014;306(8):L736-48. doi:10.1152/ajplung.00210.2013.
20. Reese C, Lee R, Bonner M, Perry B, Heywood J, Silver RM, et al. Fibrocytes in the fibrotic lung: altered phenotype detected by flow cytometry. Frontiers in Pharmacol. 2014;5:141. doi:10.3389/fphar.2014.00141.
21. Christmann RB, Hayes E, Pendergrass S, Padilla C, Farina G, Affandi AJ, et al. Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension. Arthritis Rheum. 2011;63(6):1718-28. doi:10.1002/art.30318.
22. Pendergrass SA, Hayes E, Farina G, Lemaire R, Farber HW, Whitfield ML, et al. Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury. PLoS One. 2010;5(8), e12106. doi:10.1371/journal.pone.0012106.
23. Carulli MT, Ong VH, Ponticos M, Shiwen X, Abraham DJ, Black CM, et al. Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation. Arthritis Rheum. 2005;52(12):3772-82. doi:10.1002/art.21396.
24. Ingersoll MA, Spanbroek R, Lottaz C, Gautier EL, Frankenberger M, Hoffmann R, et al. Comparison of gene expression profiles between human and mouse monocyte subsets. Blood. 2010;115(3):e10-9. doi:10.1182/blood-2009-07-235028.
25. Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat Rev Immunol. 2011;11(11):762-74. doi:10.1038/nri3070.
26. Tokuda A, Itakura M, Onai N, Kimura H, Kuriyama T, Matsushima K. Pivotal role of CCR1-positive leukocytes in bleomycin-induced lung fibrosis in mice. J Immunol. 2000;164(5):2745-51.
27. Moore BB, Kolodsick JE, Thannickal VJ, Cooke K, Moore TA, Hogaboam C, et al. CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am J Pathol. 2005;166(3):675-84.
28. Arai M, Ikawa Y, Chujo S, Hamaguchi Y, Ishida W, Shirasaki F, et al. Chemokine receptors CCR2 and CX3CR1 regulate skin fibrosis in the mouse model of cytokine-induced systemic sclerosis. J Dermatol Sci. 2013;69(3):250-8. doi:10.1016/j.jdermsci.2012.10.010.
29. Yanaba K, Komura K, Kodera M, Matsushita T, Hasegawa M, Takehara K, et al. Serum levels of monocyte chemotactic protein-3/CCL7 are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Ann Rheum Dis. 2006;65(1):124-6. doi:10.1136/ ard.2005.040782.
30. Ong VH, Evans LA, Shiwen X, Fisher IB, Rajkumar V, Abraham DJ, et al. Monocyte chemoattractant protein 3 as a mediator of fibrosis: overexpression in systemic sclerosis and the type 1 tight-skin mouse. Arthritis Rheum. 2003;48(7):1979-91. doi:10.1002/art.11164.
31. Ong VH, Carulli MT, Xu S, Khan K, Lindahl G, Abraham DJ, et al. Cross-talk between MCP-3 and TGFbeta promotes fibroblast collagen biosynthesis. Exp Cell Res. 2009;315(2):151-61. doi:10.1016/j.yexcr.2008.11.001.
32. Denton CP, Shi-Wen X, Sutton A, Abraham DJ, Black CM, Pearson JD. Scleroderma fibroblasts promote migration of mononuclear leucocytes across endothelial cell monolayers. Clin Exp Immunol. 1998;114(2):293-300.
33. Distler JH, Jungel A, Caretto D, Schulze-Horsel U, Kowal-Bielecka O, Gay RE, et al. Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. Arthritis Rheum. 2006;54(1):214-25. doi:10.1002/art.21497.
34. Yamamoto T, Nishioka K. Role of monocyte chemoattractant protein-1 and its receptor, CCR-2, in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol. 2003;121(3):510-6. doi:10.1046/j.1523-1747.2003.12408.x.
35. Todd NW, Luzina IG, Atamas SP. Molecular and cellular mechanisms of pulmonary fibrosis. Fibrogenesis Tissue Repair. 2012;5(1):11. doi:10.1186/ 1755-1536-5-11.
36. Parsons SJ, Parsons JT. Src family kinases, key regulators of signal transduction. Oncogene. 2004;23(48):7906-9. doi:10.1038/sj.onc.1208160.
37. Marudamuthu AS, Shetty SK, Bhandary YP, Karandashova S, Thompson M, Sathish V, et al. Plasminogen activator inhibitor-1 suppresses pro-fibrotic responses in fibroblasts from fibrotic lungs. J Biol Chem. 2015. doi:10.1074/ jbc.M114.601815.
38. Del Galdo F, Lisanti MP, Jimenez SA. Caveolin-1, transforming growth factor-beta receptor internalization, and the pathogenesis of systemic sclerosis. Curr Opin Rheumatol. 2008;20(6):713-9.
39. Vettori S, Cuomo G, Iudici M, D'Abrosca V, Giacco V, Barra G, et al. Early systemic sclerosis: serum profiling of factors involved in endothelial, T-cell, and fibroblast interplay is marked by elevated interleukin-33 levels. J Clin Immunol. 2014;34(6):663-8. doi:10.1007/s10875-014-0037-0.
40. Skhirtladze C, Distler O, Dees C, Akhmetshina A, Busch N, Venalis P, et al. Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum. 2008;58(5):1475-84. doi:10.1002/art.23436.
41. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest. 2004;114(9):1308-16. doi:10.1172/JCI19603.
42. Subcommittee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980;23(5):581-90.